FDA approves cheaper version of top-selling diabetes drug

Federal health officials have approved a cheaper version of the world’s top-selling insulin from Sanofi for U.S. patients with the most common form of diabetes. The Food and Drug Administration approved a new form of Sanofi’s pen-like injector, called Lantus, from drugmakers Eli Lilly and Boehringer Ingelheim.